Trial
NCT02044822
Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
Intervention
Idelalisib
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-11-19